Weight loss technology based on the principle that less is more.
Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize treatment of chronic disease. As a company, we believe in the fundamental value of imagination and invention, combined with rigorous testing and analysis, to ensure the highest levels of safety and performance. The result is a user-focused approach that deploys the power of advanced technological thinking to support clinical treatment objectives.
Extraordinarily experienced in healthcare innovation.
Andrew Rasdal has served as our President and Chief Executive Officer and a member of our board of directors since June 2008. Mr. Rasdal brings more than 25 years of medical technology experience, including serving as CEO of DexCom, Inc., Senior Vice President and President of Vascular for Medtronic, Inc., and Vice President of Marketing for Arterial Vascular Engineering.
William J. Plovanic has served as our Chief Financial Officer since March 2016. Prior to joining Obalon, Mr. Plovanic worked for 20 years as an equity research analyst covering medical device companies. From February 2007 to March 2016, Mr. Plovanic served as a Managing Director, Medical Technology Equity Research Analyst at Canaccord Genuity, Inc., a global, full-service investment bank.
Mark Brister has served as our Vice President of Research and Development since June 2008. Mr. Brister has an extensive history of developing novel technology platforms that have served as the foundation for creating successful companies. Mr. Brister was Vice President of R&D for DexCom, Inc., Vice President of Vascular R&D for Medtronic, Inc., and Vice President of R&D for Arterial Vascular Engineering.
Nooshin Hussainy has served as our Vice President of Finance since December 2011. Ms. Hussiany has over 20 years of experience in high growth companies ranging from Fortune 100 to venture-backed start-ups, including DexCom, Inc., GenMark Diagnostics, and Active Network. Ms. Hussainy has completed 2 IPOs in medical devices and diagnostics, secondary offerings, and debt offerings.
Steve Johnson has served as our Vice President of Operations since January 2014. Mr. Johnson brings more than 30 years of medical device manufacturing, product development and quality systems experience with reusable, disposable and implantable products. Mr. Johnson held Vice President positions with Advanced Cardiovascular Systems, Inc. (Abbott Vascular), Heartport, Inc., Aptus Endosystems, Inc., and iRhythm Technologies, Inc. prior to joining Obalon.
Amy VandenBerg has served as our Vice President of Regulatory Affairs since February 2012 and assumed the Vice President of Clinical and Regulatory Affairs position in November 2014. Ms. VandenBerg joined Obalon in 2008 as Director of Regulatory Affairs. Prior to joining Obalon, Ms. VandenBerg held positions of increasing leadership at other medical device companies, including Dexcom, Inc. and Cygnus. She has more than 18 years of experience with a focus on medical device quality systems, clinical affairs as well as domestic and international regulatory affairs.
Donald Young has served as our Vice President of Quality Assurance since June 2016. Mr. Young brings more than 25 years of experience in high level quality and regulatory roles, most recently serving as Sr. Director of Quality Assurance and Regulatory Affairs at CareFusion. Prior to CareFusion, Mr. Young spent 21 years in increasing leadership roles serving as Vice President of Quality Assurance and Regulatory Affairs at Flex Medical, a Division of Flextronics, formally Avail Medical and Pacific Device.
Lisa Metzner has served as our Vice President of Marketing since June 2016. Ms. Metzner has over 20 years of experience in the medical device, aesthetics, and consumer products industries. Most recently Ms. Metzner was the Sr. Director, North America Marketing for Zeltiq Aesthetics, a medical technology company. She has served as Director, Aesthetics Marketing at Medicis, Senior Manager of Consumer Marketing at Allergan, Inc. and Senior Marketing Manager at Conagra Foods.
Matt Norwood has served as our Vice President of Sales since July 2016. Mr. Norwood is a sales and marketing leader with over 15 years of experience in the capital, medical device and pharmaceutical industries. Prior to Obalon Mr. Norwood held the role of Area Director at Merz North America, device division and Sales Director at Ulthera Inc. Mr. Norwood’s career also includes sales, market development and professional education roles at Ethicon Endo-Surgery, A Johnson & Johnson Company.
Erin Morisey has served as our Vice President of Strategic Partnerships since July 2016. Ms. Morisey has over 15 years of experience in medical aesthetics, with a focus on devices. Her background includes global experience in clinical research, sales, marketing and professional education and training. Most recently Ms. Morisey served as Director of Strategic Partnerships for Merz North America. Prior to Merz, she spent almost 10 years with Zeltiq Aesthetics, developing, launching and commercializing CoolSculpting.
Board of Directors
Visionaries with track records of success.
Andrew Rasdal has served as a member of our board of directors and as our President and Chief Executive Officer since June 2008. Mr. Rasdal brings more than 25 years of medical technology experience, including serving as CEO of DexCom, Inc., Senior Vice President and President of Vascular for Medtronic, Inc., and Vice President of Marketing for Arterial Vascular Engineering.
Raymond Dittamore has served as a member of our board of directors since March 2016. Mr. Dittamore retired in June 2001 as a partner of Ernst & Young LLP, an international public accounting firm, after 35 years of service. Mr. Dittamore currently serves on the board of directors of QUALCOMM Incorporated, a semiconductor and telecommunications equipment company. Mr. Dittamore previously served on the boards of directors of Life Technologies Corporation, Gen-Probe Incorporation and Digirad Corporation.
Douglas Fisher has served as a member of our board since May 2012. Dr. Fisher is currently an Executive in Residence at InterWest Partners LLC, a venture capital firm, where he has worked since March 2009. Dr. Fisher also serves as the Chief Business Officer at Sera Prognostics, Inc., where he has worked since January 2015. Prior to joining InterWest, Dr. Fisher served as Vice President of New Leaf Venture Partners LLC, a private equity and venture capital firm, from January 2006 to March 2009. Prior to joining New Leaf, Dr. Fisher was a project leader with The Boston Consulting Group, Inc., a global management consulting firm, from November 2003 to February 2006.
Les Howe has served as a member of our board of directors since January 2016. Mr. Howe served as the Chief Executive Officer of Consumer Networks LLC, an internet marketing and promotions company, from December 2001 to May 2007. From July 1967 to September 1997, Mr. Howe held several positions at KPMG Peat Marwick LLP, an international auditing and accounting firm, and served as area managing partner/managing partner of their Los Angeles office from May 1994 to September 1997.
Kim Kamdar, Ph.D. has served as a member of our board of directors since January 2008. Dr. Kamdar is currently a partner at Domain Associates, LLC, a venture capital firm, where she has worked since 2005. Prior to Domain, Dr. Kamdar was a Kauffman Fellow with MPM Capital, as well as a research director at Novartis International AG.
Sharon Stevenson, DVM Ph.D. has served as a member of our board since January 2008. Dr. Stevenson is currently a Co-Founder and Managing Director of Okapi Venture Capital, a venture capital company, where she has worked since 2005. Prior to founding Okapi, Dr. Stevenson was the Senior Vice President of Technology and Planning for SkinMedica, Inc. (acquired by Allergan, Inc.) from 2003 to 2004. Prior to SkinMedica, Dr. Stevenson was a Principal with Domain Associates, LLC from 2000 to 2003. While at Domain, Dr. Stevenson also served as President and Chief Financial Officer of Volcano Corporation.
Deeply engaged in advancing healthcare.
Obalon Therapeutics, Inc was founded in 2008 and is backed by the following: